Cambridge Healthtech Institute’s Third Annual

Circulating Cell-Free DNA

Clinical Directions and Emerging Avenues for Early Detection

March 10-11, 2016 | Hilton San Francisco Union Square | San Francisco, CA
Part of the 23rd International Molecular Medicine Tri-Conference

 

Circulating cell-free DNA (cfDNA) currently allows for minimal residual disease detection and treatment monitoring with new clinical data emerging regularly. However, as technology evolves and assays increase in sensitivity, the possibility of earlier detection will become more of a reality. At Cambridge Healthtech Institute’s Third Annual Circulating Cell-Free DNA, leading researchers from academia and industry will come together to address advances as well as existing challenges in this rapidly growing field. This year’s event will place emphasis on early detection, clinical validation of assay sensitivity and specificity, and establishing standards for cfDNA.

Who should attend: VPs, Directors, Managers, CEOs, CSOs, Professors and Scientists from Large Pharma, Biotechs and Academia working in fields such as molecular oncology, cancer biomarkers, molecular diagnostics, translational research, genetics, and research and development.

Topics will include, but are not limited to: 

  • cfDNA for:
    • Early detection
    • Treatment monitoring
    • Minimal residual disease detection
    • Drug resistance detection
  • Applicability of cfDNA in early stage disease
  • Clinical validation of assay sensitivity and specificity
  • Clinical trial assays - what size should your panel be?
  • Clinical trial data
  • Clinical utility in comparison with tissue biopsy
  • Moving panels into routine clinical use
  • Handling negative test results
  • Working with different sample types:
    • Cerebrospinal fluid
    • Urine
    • Saliva
  • Working with small sample types
  • Integration with RNA and exosomes
  • Methylation
  • Companion diagnostic tests
  • Reimbursement of tests
  • Establishing standards for cfDNA
    • Improving consistency

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is August 7, 2015. 

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships. 

For more details on the conference, please contact:
Samantha Drinkwater
Conference Producer
Cambridge Healthtech Institute
T: (+1) 781-972-5461
E: sdrinkwater@healthtech.com 

For partnering and sponsorship information, please contact:
Jon Stroup (Companies A-K)
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com 

Joseph Vacca (Companies L-Z)
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com 

Premier Sponsors:   

Elsevier    

Jackson Laboratory - small logo  

 NanoString2    

 Precision for Medicine 

SeraCare 

Silicon Biosystems 

Thomson Reuters-Large